Addition of MPDL3280A to Bevacizumab Induces Responses in mRCC
Addition of MPDL3280A to Bevacizumab Induces Responses in mRCC
Nivolumab Approved for NSCLC
Nivolumab Approved for NSCLC
Early Intervention Essential for Proper Management of Lymphedema
Early Intervention Essential for Proper Management of Lymphedema
OncAlert   Dr. Bradley Monk discusses an ovarian cancer case study

Video Viewpoints
JTT Articles
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
Soft Tissue Sarcomas: Emerging and Novel Concepts
Mutant-Specific Epidermal Growth Factor Receptor Inhibitors
Publications
Case-Based Peer Perspectives
Special Reports
Special Reports
External Resources

MJH Associates
AJMC
Cure
HCPLive
OncLive
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.